For better understanding of the clinical relevance of the ZNF667-AS1 expression in glioma, the 155 glioma patients were split as a high expression cohort (n = 79) and a low expression cohort (n = 76), complying with the median expressing condition of ZNF667-AS1 (5.62) in all glioma samples. The gene discussed is ZNF667; the disease is central nervous system cancer.